Skip to content

Skye Bioscience, Inc.: 10-Q filed 2023-08-07

What Skye Bioscience, Inc. reported in its quarterly report filed 2023-08-07 (fiscal Q2 2023): 35 published measures, 104 facts as tagged in accession 0001516551-23-000044.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-07
Fiscal period
fiscal Q2 2023
Accession
0001516551-23-000044 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Skye Bioscience, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-302,235,944USD
At 2022-12-319,111,072USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-3010,025,142USD
At 2022-12-3112,119,126USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-30-7,789,198USD
At 2023-03-31-4,780,569USD
At 2022-12-31-3,008,054USD
At 2022-06-30-301,822USD
At 2022-03-312,973,092USD
At 2021-12-315,864,166USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-06-30553,443USD
At 2022-12-311,244,527USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-3,111,500USD91
2023-01-01 to 2023-06-30-8,279,020USD181
2023-01-01 to 2023-03-31-5,167,520USD90
2022-04-01 to 2022-06-30-3,419,278USD91
2022-01-01 to 2022-06-30-6,462,677USD181
2022-01-01 to 2022-03-31-3,043,399USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-6,052,759USD181
2022-01-01 to 2022-06-30-5,815,959USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-01-01 to 2023-06-301,860USD181
2022-01-01 to 2022-06-305,212USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-168,720USD181
2022-01-01 to 2022-06-30-151,109USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-06-305,530,406USD181
2022-01-01 to 2022-06-30-86,042USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-75,016,785USD
At 2022-12-31-66,737,765USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-04-01 to 2023-06-30971,549,608shares91
2023-01-01 to 2023-06-30956,804,028shares181
2022-04-01 to 2022-06-30495,925,112shares91
2022-01-01 to 2022-06-30495,874,560shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-04-01 to 2023-06-30971,549,608shares91
2023-01-01 to 2023-06-30956,804,028shares181
2022-04-01 to 2022-06-30495,925,112shares91
2022-01-01 to 2022-06-30495,874,560shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-04-01 to 2023-06-300USD/shares91
2023-01-01 to 2023-06-30-0.01USD/shares181
2022-04-01 to 2022-06-30-0.01USD/shares91
2022-01-01 to 2022-06-30-0.01USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-04-01 to 2023-06-300USD/shares91
2023-01-01 to 2023-06-30-0.01USD/shares181
2022-04-01 to 2022-06-30-0.01USD/shares91
2022-01-01 to 2022-06-30-0.01USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-04-01 to 2023-06-303,600USD91
2023-01-01 to 2023-06-303,600USD181
2022-04-01 to 2022-06-305,141USD91
2022-01-01 to 2022-06-305,141USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-06-3064,395USD
At 2022-12-3187,854USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-06-30234,450USD181
2022-01-01 to 2022-06-30281,722USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-2,842,997USD91
2023-01-01 to 2023-06-30-5,943,155USD181
2022-04-01 to 2022-06-30-3,218,360USD91
2022-01-01 to 2022-06-30-6,106,382USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-301,892,687USD
At 2022-12-318,943,718USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-04-01 to 2023-06-30186,429USD91
2023-01-01 to 2023-06-30204,828USD181
2022-04-01 to 2022-06-30205,300USD91
2022-01-01 to 2022-06-30404,332USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-309,816,554USD
At 2022-12-3112,119,126USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-06-301,551,510USD
At 2022-12-311,669,997USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-04-01 to 2023-06-302,842,997USD91
2023-01-01 to 2023-06-305,943,155USD181
2022-04-01 to 2022-06-303,218,360USD91
2022-01-01 to 2022-06-306,106,382USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,788,434USD91
2023-01-01 to 2023-06-302,973,314USD181
2022-04-01 to 2022-06-301,427,154USD91
2022-01-01 to 2022-06-302,692,807USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-06-30971,549,608shares
At 2022-12-31913,528,958shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-30558,034USD
At 2022-12-311,249,107USD
At 2022-06-302,934,468USD
At 2021-12-318,987,578USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-06-30270,553USD
At 2022-12-3171,191USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-06-30274,040USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-06-308,309USD
At 2022-12-318,309USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-3,107,900USD91
2023-01-01 to 2023-06-30-8,275,420USD181
2022-04-01 to 2022-06-30-3,414,137USD91
2022-01-01 to 2022-06-30-6,457,536USD181

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-3,111,500USD91
2023-01-01 to 2023-06-30-8,279,020USD181
2022-01-01 to 2022-06-30-6,462,677USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,206,405USD91
2023-01-01 to 2023-06-303,121,683USD181
2022-04-01 to 2022-06-301,791,206USD91
2022-01-01 to 2022-06-303,413,575USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-01-01 to 2023-06-3067,091USD181
2022-01-01 to 2022-06-3054,661USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-264,903USD91
2023-01-01 to 2023-06-30-2,332,265USD181
2022-04-01 to 2022-06-30-195,777USD91
2022-01-01 to 2022-06-30-351,154USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-06-308,533USD181
2022-01-01 to 2022-06-302,669USD181

Inspect the source

Entity
Skye Bioscience, Inc. / CIK 0001516551
Captured
2026-09-20T09:13:51.237Z
SEC response SHA-256
fd229875bbe9efbf8ce715b00820b845a594b6e60bad8dd4ff739bde7e7cfc9e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001516551.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))